Avidity Biosciences

News

Novartis takes $1.9bn hit from Avidity takeover in Q3

Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.

News

Novartis gets win for another Avidity muscular dystrophy AOC

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

New biotech Atrium born out of Novartis/Avidity marriage

Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.

News

Novartis makes $12bn wager on RNA drugs with Avidity buy

Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy RNA specialist Avidity Biosciences for $12bn.

News

Rumour mill says Novartis may want to buy Avidity

Novartis has made an offer to acquire RNA therapeutic specialist Avidity Biosciences, according to an unconfirmed report.

News

Buoyed by muscular dystrophy data, Avidity raises $345m

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an imp

Novartis takes $1.9bn hit from Avidity takeover in Q3

Novartis gets win for another Avidity muscular dystrophy AOC

New biotech Atrium born out of Novartis/Avidity marriage

Novartis makes $12bn wager on RNA drugs with Avidity buy

Rumour mill says Novartis may want to buy Avidity

Buoyed by muscular dystrophy data, Avidity raises $345m

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Avidity Biosciences

Editor's Picks